<DOC>
	<DOCNO>NCT00485030</DOCNO>
	<brief_summary>To evaluate best therapeutic option treatment diffuse type post-drug-eluting stent restenosis .</brief_summary>
	<brief_title>Diffuse Type In-Stent Restenosis After Drug-Eluting Stent</brief_title>
	<detailed_description>Despite significant reduction angiographic restenosis need repeat revascularization introduction DES , post-DES restenosis still occur treatment DES failure challenge . However , little data therapeutic strategy post-DES restenosis , especially diffuse type ISR . Therefore , need well-designed randomized trial achieve best therapeutic option treatment diffuse type post-DES restenosis .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . The patient must least 18 year age . 2 . Restenosis drugeluting stent ( &gt; 50 % visual estimate ) 3 . Lesion length â‰¥ 10 mm ( diffuse type ISR ) 4 . Patients stable ( CCS class 1 4 ) acute coronary syndrome ( unstable angina pectoris Braunwald class IB , IC , IIB , IIC , IIIB , IIIC NSTEMI ) patient atypical chest pain without symptom document myocardial ischemia , amenable stentassisted percutaneous coronary intervention 5 . The patient guardian agrees study protocol schedule clinical angiographic followup , provide informed , write consent , approve appropriate Institutional Review Board/Ethical Committee respective clinical site . 1 . The patient know hypersensitivity contraindication follow medication : Heparin Aspirin Both Clopidogrel TIclopidine Sirolimus elute stent Stainless steel and/or Contrast medium ( patient document sensitivity contrast effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Patients true anaphylaxis prior contrast medium , however , enrol ) . 2 . Systemic ( intravenous ) Sirolimus use within 12 month . 3 . Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study . 4 . History bleed diathesis know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion . 5 . Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month . 6 . Current know current platelet count &lt; 100,000 cells/mm3 Hgb &lt; 10 g/dL . 7 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . 8 . Patients actively participate another drug device investigational study , complete primary endpoint followup period . 9 . Patients EF &lt; 30 % . 10 . Acute MI patient within symptom onset &lt; 12 hour need primary angioplasty 11 . Creatinine level 3.0mg/dL dependence dialysis . 12 . Severe hepatic dysfunction ( AST ALT 3 time upper normal reference value ) . 13 . Patients leave main stem stenosis leave main instent restenosis create DES ( &gt; 50 % visual estimate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>stent</keyword>
	<keyword>angioplasty</keyword>
</DOC>